NCT06165991View on ClinicalTrials.gov

Efficacy and Safety of Liposomal Bupivacaine in Thoracic Paravertebral Nerve Block

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Thoracic Paravertebral BlockPostoperative AnalgesiaThoracoscopic Lobectomy

Interventions

DRUG

Liposomal bupivacaine, Bupivacaine

"1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block complex PCIA;~1.33% (liposomal bupivacaine, LB) 20mL thoracic paravertebral nerve block combined with drainage tube analgesia technique combined with PCIA"

Trial Locations (1)

250014

Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University, Jinan

All Listed Sponsors

lead

Yongtao Sun

OTHER

NCT06165991 - Efficacy and Safety of Liposomal Bupivacaine in Thoracic Paravertebral Nerve Block | Biotech Hunter | Biotech Hunter